Fantastic reading, as expected.
I have confidence in their approach below - which history show is exactly what they did for PhII for Trof - and we all know how that turned out
"In order to accelerate the overall development plan, in parallel with conducting the Phase 2 trials Neuren is executing the additional development work
required to be ready for Phase 3 development. This includes non-clinical toxicity studies to support longer clinical trials and commercial use of the product as well as optimisation of the drug product and drug substance manufacturing arrangements."
Ann: Q4 2023 quarterly activity report, page-2
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.72 |
Change
-0.150(0.72%) |
Mkt cap ! $2.648B | |||
| Open | High | Low | Value | Volume |
| $20.96 | $21.28 | $20.61 | $4.984M | 239.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 782 | $20.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.72 | 1021 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |